SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mark Joachim)
 

Sökning: WFRF:(Mark Joachim) > Human Epidermal Gro...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005567naa a2200541 4500
001oai:DiVA.org:uu-514020
003SwePub
008231013s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:154436277
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5140202 URI
0247 a https://doi.org/10.2967/jnumed.122.2653642 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1544362772 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Alhuseinalkhudhur, Aliu Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)alial794
2451 0a Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
264 1b Society of Nuclear Medicine,c 2023
338 a electronic2 rdacarrier
520 a Imaging using the human epidermal growth factor receptor 2 (HER2)-binding tracer 68Ga-labeled ZHER2:2891-Cys-MMA-DOTA ([68Ga]Ga-ABY-025) was shown to reflect HER2 status determined by immunohistochemistry and in situ hybridization in metastatic breast cancer (MBC). This single-center open-label phase II study investigated how [68Ga]Ga-ABY-025 uptake corresponds to biopsy results and early treatment response in both primary breast cancer (PBC) planned for neoadjuvant chemotherapy and MBC. Methods: Forty patients with known positive HER2 status were included: 19 with PBC and 21 with MBC (median, 3 previous treatments). [68Ga]Ga-ABY-025 PET/CT, [18F]F-FDG PET/CT, and core-needle biopsies from targeted lesions were performed at baseline. [18F]F-FDG PET/CT was repeated after 2 cycles of therapy to calculate the directional change in tumor lesion glycolysis (Δ-TLG). The largest lesions (up to 5) were evaluated in all 3 scans per patient. SUVs from [68Ga]Ga-ABY-025 PET/CT were compared with the biopsied HER2 status and Δ-TLG by receiver operating characteristic analyses. Results: Trial biopsies were HER2-positive in 31 patients, HER2-negative in 6 patients, and borderline HER2-positive in 3 patients. The [68Ga]Ga-ABY-025 PET/CT cutoff SUVmax of 6.0 predicted a Δ-TLG lower than -25% with 86% sensitivity and 67% specificity in soft-tissue lesions (area under the curve, 0.74 [95% CI, 0.67-0.82]; P = 0.01). Compared with the HER2 status, this cutoff resulted in clinically relevant discordant findings in 12 of 40 patients. Metabolic response (Δ-TLG) was more pronounced in PBC (-71% [95% CI, -58% to -83%]; P < 0.0001) than in MBC (-27% [95% CI, -16% to -38%]; P < 0.0001), but [68Ga]Ga-ABY-025 SUVmax was similar in both with a mean SUVmax of 9.8 (95% CI, 6.3-13.3) and 13.9 (95% CI, 10.5-17.2), respectively (P = 0.10). In multivariate analysis, global Δ-TLG was positively associated with the number of previous treatments (P = 0.0004) and negatively associated with [68Ga]Ga-ABY-025 PET/CT SUVmax (P = 0.018) but not with HER2 status (P = 0.09). Conclusion: [68Ga]Ga-ABY-025 PET/CT predicted early metabolic response to HER2-targeted therapy in HER2-positive breast cancer. Metabolic response was attenuated in recurrent disease. [68Ga]Ga-ABY-025 PET/CT appears to provide an estimate of the HER2 expression required to induce tumor metabolic remission by targeted therapies and might be useful as an adjunct diagnostic tool.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Radiologi och bildbehandling0 (SwePub)302082 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Radiology, Nuclear Medicine and Medical Imaging0 (SwePub)302082 hsv//eng
653 a HER2 positive
653 a PET/CT
653 a [68Ga]Ga-ABY-025
653 a affibody molecules
653 a breast cancer
7001 a Lindman, Henriku Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)henrlind
7001 a Liss, Per,d 1960-u Uppsala universitet,Radiologi4 aut0 (Swepub:uu)perliss
7001 a Sundin, Tora4 aut
7001 a Frejd, Fredrik Y.u Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)freni195
7001 a Hartman, Johanu Karolinska Institutet4 aut
7001 a Iyer, Victoru Uppsala universitet,Radiologi4 aut0 (Swepub:uu)viciy101
7001 a Feldwisch, Joachim4 aut
7001 a Lubberink, Marku Uppsala universitet,Radiologi,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)marklubb
7001 a Rönnlund, Caroline4 aut
7001 a Tolmachev, Vladimiru Uppsala universitet,Institutionen för immunologi, genetik och patologi4 aut0 (Swepub:uu)vladtolm
7001 a Velikyan, Irina,d 1966-u Uppsala universitet,Radiologi,Translationell avbildning med PET4 aut0 (Swepub:uu)irinveli
7001 a Sörensen, Jensu Uppsala universitet,Radiologi4 aut0 (Swepub:uu)jenssore
7102 a Uppsala universitetb Institutionen för immunologi, genetik och patologi4 org
7730 t Journal of Nuclear Medicined : Society of Nuclear Medicineg 64:9, s. 1364-1370q 64:9<1364-1370x 0161-5505x 1535-5667
8564 u https://doi.org/10.2967/jnumed.122.265364y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1804655/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-514020
8564 8u https://doi.org/10.2967/jnumed.122.265364
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154436277

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy